OutSee has completed the final close of a £2.5 million pre-seed round, with Empirical Ventures, to advance its AI drug-target discovery platform.
OutSee's Nomaly platform integrates protein-domain knowledge, phenotype ontologies and statistical clustering to identify genetic outliers.
The new capital will help the team accelerate development and bring the technology closer to market.
